SEC Comment Letter 0000000000-24-010266 to Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc
Date: Sept. 11, 2024 · CIK: 0001541157 · Accession: 0000000000-24-010266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281995
Letter
September 11, 2024 Samir R. Patel Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re:Akari Therapeutics, Plc Registration Statement on Form S-3 Filed September 6, 2024 File No. 333-281995 Dear Samir R. Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Justin Platt, Esq.
Show Raw Text
September 11, 2024
Samir R. Patel
Chief Executive Officer
Akari Therapeutics, Plc
22 Boston Wharf Road FL 7
Boston, MA 02210
Re:Akari Therapeutics, Plc
Registration Statement on Form S-3
Filed September 6, 2024
File No. 333-281995
Dear Samir R. Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Justin Platt, Esq.